General Conditions for the use of Galenicum Health, S.L.U. website
Galenicum Health, S.L.U., as the controller of the processing, guarantees an adequate and consistent standard of protection of natural persons concerning their personal data that is subject to processing by the company, in accordance with the General Data Protection Regulation (2016/679).
Galenicum Health, S.L.U. only processes personal data responsibly and diligently, and in accordance with the lawful basis that enables the processing. It has also taken the required and appropriate security measures against the risks that have been objectively evaluated and identified to the rights and freedoms of interested persons, which the processing carried out by our company might lead to.
Below, we offer extensive additional information regarding the specific processing activities carried out by Galenicum Health, S.L.U. via its website:
ADDITIONAL DATA PROTECTION INFORMATION
Name: Galenicum Health, S.L.U.
Company tax number (NIF): B63078075
Postal address: Av. Diagonal 123, 11th Floor, 08005 Barcelona, Spain
Telephone No.: +34 932 011 750
Email address: email@example.com
The purpose of data processing and retention
Galenicum Health, S.L.U. shall process your personal data in order to:
Once the purpose for which your data have been collected has been fulfilled, they shall be destroyed and only the data required to deal with complaints or to comply with applicable legislation shall be retained.
Legitimation for the processing
The lawful basis that authorises us to process your data is the consent provided by you when you contact us online, or public interest in the public health sphere in the case of pharmacovigilance.
Recipients of your data
Your data shall not be communicated to third parties, except for group companies for internal administrative management and if required by legal provisions.
Rights of the interested party
Users of www.galenicumaxium.com, shall be entitled to:
To exercise your rights, you must contact us by email, attaching a copy of your national identification document (DNI) at our email address: firstname.lastname@example.org, if you are not satisfied you may contact the Spanish Data Protection Agency via its website: www.aepd.es.
The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.
The products mentioned may have a different authorized data sheet in each country.
If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.
DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.